Nationwide Retirement Institute 2026 Social Security Survey shows 80% of Americans (82% Democrats, 78% Republicans) agree system needs to change — bipartisan consensus rare in polarized climate: Top three solutions ranked identically across party lines: (1) Raise taxes on higher earners to increase funding — 51% overall (56% Democrats, 43% Republicans); (2) Raise employer payroll taxes — 42% overall (44% Democrats, 42% Republicans); (3) Reduce/eliminate benefits for high-income individuals — 38% overall (even split 38% Democrats, 37% Republicans).

Workers currently pay Social Security tax on first $184,500 earnings; anything above escapes tax — proposals include scrapping cap entirely or applying higher rate on earnings above $400K: Most popular approach taxes high earners while protecting middle/low-income retirees and workers — demonstrates broad support for progressive solution — Republican support 43% for high-earner tax vs. 56% Democrat support shows narrowest party divide is on revenue source, not need for action.

Despite 61% expecting government will act before benefits cut in 2032, only 20% know how they'd adjust finances if reduction occurred: Americans underestimate urgency, believing depletion 17 years away when actually Q4 2032 (6 years) — Peter G. Peterson Foundation poll found 96% say Senate candidates must explain prevention plans, creating electoral mandate — without Congressional action, automatic 22% benefit cut affects 70M beneficiaries.

Committee for Responsible Federal Budget analysis shows retirees this decade receiving 133% of combined worker/employer payroll tax contributions (265% of worker's own share alone): Median-wage retiree in 2027 expects $730,000 lifetime benefits from less than $200,000 in personal taxes; benefits exceed contributions within just three years — bottom income quintile collects 266% of combined taxes (532% of their own contributions) — even wealthiest retirees collect roughly double their direct payments — surplus not funded by accumulated boomer savings but current workers' payroll taxes.

Worker-to-beneficiary ratio collapsed from 16:1 in 1950 to 2.7:1 today, heading toward 2:1 within decades: Fewer workers splitting cost of supporting larger, longer-living retired population — current benefit formula paying 35% more than collected in revenue over next 75 years — same formula paying 33% more than collected today — mathematical breakdown requires structural reform, not individual blame on boomers who paid decades into system.

Social Security trust fund depletes Q4 2032 triggering automatic 22% across-the-board benefit cut affecting all beneficiaries unless Congress acts: Millennials/Gen X increasingly funding boomer benefits while uncertain they'll receive their own — CRFB warns existing benefit formula "untouchable" framing prevents necessary adjustments — describes pattern of "pig in the python" (baby boom bulge distorting economy at each life stage) reshaping systems built for smaller cohorts.

CVS and Walgreens each filled approximately 100,000 obesity drug prescriptions since July 1 launch of Medicare Bridge pilot program; Walmart processing prescriptions weekly at 5,000+ locations nationwide: CMS Administrator Oz reported 250,000 beneficiaries signed up by late July (though unclear how many received prior authorization approval) — strong uptake suggests seniors eager for affordable weight-loss drug access — roughly 4 million Medicare beneficiaries eligible; 200,000 prescriptions filled in two months represents 5-10% penetration of eligible population in short timeframe.

Program workaround allows Medicare coverage for GLP-1s (Wegovy, Zepbound, Foundayo) at $50/month copay for beneficiaries meeting obesity-plus-condition criteria: Eligible beneficiaries must have obesity combined with high blood pressure (difficult to control), cardiovascular disease, or other specified conditions — excludes Type 2 diabetes and sleep apnea patients (Medicare Part D should cover those) — even though GLP-1s proven effective for excluded conditions — temporary pilot runs through end of 2027.

Cost-benefit debate centers on long-term value preventing disease progression rather than upfront drug expenses: KFF estimates Bridge program cost between $1.3B-$10B over 18 months depending on participation rates — USC research suggests long-term savings if GLP-1s reduce hospitalizations, dialysis, complications from chronic disease — Walgreens reports roughly half of Bridge patients new to GLP-1s; pharmacy support critical for managing initial side effects (nausea, diarrhea) that could cause early discontinuation.